Aditxt Launches Bitcoin-Backed bitXbio™ Program to Accelerate Biotechnology Commercialization

On July 7th, US-listed company Aditxt, Inc. (Nasdaq: ADTX) announced today the launch of the bitXbio™ program, an innovative fiscal policy strategy combining Bitcoin reserves with equity financing. The program aims to support the company's biotechnology commercialization efforts, particularly towards potential monetization events in 2026, including the planned IPO of its subsidiary Pearsanta. Aditxt, which currently operates two projects focused on autoimmunity and early disease detection, will build Bitcoin reserves based on funding availability and strategically utilize its existing approximately $125.00 million equity financing facility. CEO Amro Albanna stated that this move will help Aditxt strengthen its balance sheet and enhance corporate value, creating more value for shareholders. [Deep Tide TechFlow]